Table 2.
Demographic, clinical, and histologic variables by APOL1 risk status (all subjects)
| Variable | Zero or One APOL1 Risk Alleles | Two APOL1 Risk Alleles | P Value |
|---|---|---|---|
| Number of subjects | 67 | 27 | |
| Onset age (yr) | 13 (8, 23) | 17 (13, 27) | 0.03 |
| Enrollment age (yr) | 14 (10, 28) | 17 (13, 27) | 0.07 |
| Baseline eGFR (ml/min per 1.73 m2) | 130 (83, 195) | 94 (68, 109) | 0.003 |
| Baseline serum albumin (g/dl) | 3.1 (2.3, 3.7) | 3.0 (2.1, 3.8) | 0.84 |
| Baseline urine protein-to-creatinine ratio | 3.6 (2.2, 7.1) | 4.7 (2.8, 10.2) | 0.28 |
| Baseline serum suPAR (ng/ml) | 4297 (3402, 5405) | 4020 (3104, 4510) | 0.18 |
| Change in suPAR (ng/ml) | −27 (−1062, +764) | +103 (−532, +1541) | 0.33 |
| FSGS histologic variant | 0.02 | ||
| Collapsing | 3 | 8 | |
| Tip | 10 | 2 | |
| Cellular | 2 | 0 | |
| Perihilar | 7 | 2 | |
| Not otherwise specified | 45 | 15 | |
| Segmental glomerulosclerosis (%) | 20 (9, 31) | 25 (19, 34) | 0.02 |
| Global glomerulosclerosis (%) | 0 (0, 12) | 7 (0, 17) | 0.43 |
| Total glomerulosclerosis (%) | 25 (12, 50) | 44 (24, 62) | 0.02 |
| Tubular atrophy/fibrosis (%) | 10 (5, 25) | 20 (5, 60) | <0.01 |
| Arteriosclerosis (score) | 0 (0, 1) | 0 (0, 1.2) | 0.13 |
| CR (remissions coded as one or two) | 11 | 1 | 0.17 |
| CR or PR sustained at week 52 (remission coded as one, two, or three) | 29 | 7 | 0.16 |
| Reached end stage kidney disease during the follow-up period | 8 | 10 | <0.01 |
Data are presented as medians (25th, 75th percentiles). Note that the total glomerulosclerosis is not the sum of segmental glomerulosclerosis plus global glomerulosclerosis, because the values are medians.